Document Detail


Cost-effectiveness analysis of Paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.
MedLine Citation:
PMID:  24325699     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Purpose : To explore the cost-effectiveness of using drug-eluting balloon (DEB) angioplasty for the treatment of femoropopliteal arterial lesions, which has been shown to significantly lower the rates of target lesion revascularization (TLR) compared with standard balloon angioplasty (BA). Methods : A simplified decision-analytic model based on TLR rates reported in the literature was applied to baseline and follow-up costs associated with in-hospital patient treatment during 1 year of follow-up. Costs were expressed in Swiss Francs (sFr) and calculated per 100 patients treated. Budgets were analyzed in the context of current SwissDRG reimbursement figures and calculated from two different perspectives: a general budget on total treatment costs (third-party healthcare payer) as well as a budget focusing on the physician/facility provider perspective. Results : After 1 year, use of DEB was associated with substantially lower total inpatient treatment costs when compared with BA (sFr 861,916 vs. sFr 951,877) despite the need for a greater investment at baseline related to higher prices for DEBs. In the absence of dedicated reimbursement incentives, however, use of DEB was shown to be the financially less favorable treatment approach from the physician/facility provider perspective (12-month total earnings: sFr 179,238 vs. sFr 333,678). Conclusion : Use of DEBs may be cost-effective through prevention of TLR at 1 year of follow-up. The introduction of dedicated financial incentives aimed at improving DEB reimbursements may help lower total healthcare costs.
Authors:
Nicolas Diehm; Henrique Schneider
Related Documents :
24334719 - Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate- and...
23125899 - Impact of antiplatelet treatment on colorectal cancer staging characteristics.
23006489 - Cost-effectiveness of cardiac resynchronization therapy: perspective from argentina.
23701059 - Effect of intraparenchymal blood patch on rates of pneumothorax and pneumothorax requir...
23775099 - Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid scl...
22902419 - Evaluating the effectiveness of multidisciplinary low-vision rehabilitation.
10150319 - Cefadroxil in skin and skin-structure foot infections: a retrospective review.
22184469 - Timing of susceptibility-based antifungal drug administration in patients with candida ...
16919209 - Correction of moderate to severe hallux valgus deformity by a modified chevron shaft os...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists     Volume:  20     ISSN:  1545-1550     ISO Abbreviation:  J. Endovasc. Ther.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100896915     Medline TA:  J Endovasc Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  819-25     Citation Subset:  IM    
Affiliation:
1 Clinical and Interventional Angiology, Swiss Cardiovascular Center, Inselspital, University Hospital Bern, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of Chronic SFA In-Stent Occlusion With Combined Laser Atherectomy and Drug-Eluting Balloon...
Next Document:  Quantification of popliteal artery deformation during leg flexion in subjects with peripheral artery...